Table 1 Tumor growth parameters of VALD-3 treatment on the breast cancer xenografts model.

From: VALD-3, a Schiff base ligand synthesized from o-vanillin derivatives, induces cell cycle arrest and apoptosis in breast cancer cells by inhibiting the Wnt/β-catenin pathway

Group

Animal weight

Tumor volume

Tumor weight (g)

Inhibition rate (IR) (%)

Initial (g)

Sacrificed (g)

Initial (cm3)

Sacrificed (cm3)

Control

18.27 ± 0.77

17.66 ± 0.48

0.48 ± 0.22

3.01 ± 0.39

2.32 ± 0.53

0.00

Cisplatin (5 mg/kg/3d)

17.61 ± 0.71

14.90 ± 0.87

0.55 ± 0.25

1.52 ± 0.44

0.99 ± 0.44*

57.40

VALD-3 (20 mg/kg/d)

17.94 ± 0.55

17.83 ± 0.73

0.53 ± 0.20

2.03 ± 0.35

1.14 ± 0.30*

51.00

VALD-3 + Cisplatin

17.97 ± 0.34

14.69 ± 0.97

0.51 ± 0.21

1.11 ± 0.29

0.97 ± 0.36*

58.20

  1. *P < 0.05 compared with the control group with significant differences.
Back to article page